Active Stocks
Tue Mar 19 2024 14:11:06
  1. Tata Consultancy Services share price
  2. 3,990.00 -3.73%
  1. Tata Steel share price
  2. 149.50 -0.07%
  1. Bharti Airtel share price
  2. 1,232.20 0.58%
  1. Power Grid Corporation Of India share price
  2. 260.30 -1.77%
  1. ITC share price
  2. 409.50 -1.89%
Business News/ Companies / News/  Glenmark shares rise on Salix drug approval
BackBack

Glenmark shares rise on Salix drug approval

Glenmark will be manufacturing and supplying the drug to Salix for the US market

Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. (Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. )Premium
Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement.

(Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement. )

Mumbai: Shares of drug maker Glenmark Pharmaceuticals Ltd rose as much as 3.4% in intra-day trade as its US partner Salix Pharma Inc. received regulatory approval for selling crofelemer, a new drug for treating diarrhoea in HIV/ Aids patients.

Glenmark will be manufacturing and supplying the drug to Salix for the US market.

Crofelemer has been in-licensed from Napo by Salix and Glenmark, which have the right to commercially manufacture and develop the drug in various markets, brokerage Edelweiss Securities said in a Tuesday report.

Salix has paid $15 million to Glenmark as part of the manufacturing and supply agreement, and the Indian drug maker expects at least $15 million annually in revenue from the sales of crofelemer in the US for the next few years.

The Glenmark stock also had a boost recently after the company’s wholly owned unit signed an agreement with Forest Laboratories Inc. on 24 December to collaborate for the development of mPGES-1 inhibitors to treat chronic inflammatory conditions.

The US-based Forest Lab will pay $6 million upfront to Glenmark and an additional $3 million to support the next phase of development. Forest will make other payments in financial year 2013-14 to support the advancement of the mPGES-1 inhibitors program.

On Tuesday, Glenmark shares, which had jumped 81.5% in 2012, gained 2.3% to close at Rs539.75 on BSE Ltd. The 30-share benchmark Sensex climbed 0.8% to 19,580.81 points.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 01 Jan 2013, 07:19 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie